Molecular imaging of neuroendocrine tumors
K Öberg - Expert review of endocrinology & metabolism, 2008 - Taylor & Francis
Molecular imaging represents tissue-specific imaging and quantification of physiologically
functional and molecular events in tumors, utilizing new noninvasive imaging modalities. It …
functional and molecular events in tumors, utilizing new noninvasive imaging modalities. It …
Individualized molecular cancer therapy based on radiolabelled somatostatin analogues
M Gabriel, U Andergassen, IJ Virgolini - memo-Magazine of European …, 2008 - Springer
In recent years, different therapeutic approaches have emerged for individualized targeted
therapy in tumour patients. It was found that tumours derived from neuroendocrine tissue …
therapy in tumour patients. It was found that tumours derived from neuroendocrine tissue …
Verbesserte intratumorale Retention in neuroendokrinen Tumoren nach intraarterieller Applikation von 131I-MIBG
C Brogsitter, J Pinkert, J Bredow, T Kittner… - Der …, 2008 - thieme-connect.com
Zusammenfassung 131 I-Metaiodobenzylguanidin (131 I-MIBG) stellt ein etabliertes
Behandlungsverfahren für neuroendokrine Tumoren dar. Aufgrund der niedrigen …
Behandlungsverfahren für neuroendokrine Tumoren dar. Aufgrund der niedrigen …
Treatment with 131I-mIBG (Metaiodobenzylguanidine): Indications, Procedures, and Results
MR Castellani, A Scarale, A Lorenzoni… - Clinical Applications of …, 2018 - Springer
Since the 80s, treatment with 131 I-metaiodobenzylguanidine (mIBG) has been introduced
in the management of neuroendocrine tumors (NET). In several chromaffin tumors …
in the management of neuroendocrine tumors (NET). In several chromaffin tumors …
Tumor Staging: Pancreas
RE Rossi, S Massironi - Neuroendocrine Tumors in Real Life: From …, 2018 - Springer
In patients with pancreatic neuroendocrine tumors (pNETs), the assessment of the tumor
extent and location and the evaluation of any possible local and/or distant metastases are …
extent and location and the evaluation of any possible local and/or distant metastases are …
Клінічні рекомендації з діагностики та лікування нейроендокринних пухлин тонкої кишки
МГ Зубарєв, ОО Колеснік, АВ Лукашенко… - Клиническая …, 2018 - irbis-nbuv.gov.ua
Нейроендокринні пухлини (НЕП) об'єднують доволі велику групу новоутворень, які
характеризуються біологічною різноманітністю та гетерогенністю. За даними …
характеризуються біологічною різноманітністю та гетерогенністю. За даними …
Production and Quality Control of Indium-111 Pentetreotide Radiopharmaceutical in Iran
SY Fazaeli Hoseini Nezhad, M Erfani - Journal of Nuclear Science …, 2017 - jonsat.nstri.ir
111In pentetreotide (OctreoScanTM) radiopharmaceutical is used extensively for the
detection of a variety of cancers in medicine. Octerotide is a pharmaceutical with a structure …
detection of a variety of cancers in medicine. Octerotide is a pharmaceutical with a structure …
[PDF][PDF] 177Lutetium-DOTATATE-Peptid-Radio-Rezeptor-Therapie bei Patienten mit neuroendokrinen Neoplasien und die individualisierte, semi-automatische …
A Löser - 2016 - rosdok.uni-rostock.de
Die Peptid-Radio-Rezeptor-Therapie (PRRT) stellt eine palliative Therapiemöglichkeit für
Patienten mit neuroendokrinen Neoplasien (NEN) dar. Während in anderen Fachgebieten …
Patienten mit neuroendokrinen Neoplasien (NEN) dar. Während in anderen Fachgebieten …
[PDF][PDF] Characterization of two microRNAs in endocrine tissue
DK Sarusie - 2015 - rucforsk.ruc.dk
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous group of
tumors that originate from various cell types belonging to the diffuse neuroendocrine system …
tumors that originate from various cell types belonging to the diffuse neuroendocrine system …
Approches de la médecine nucléaire au Liban dans les tumeurs neuroendocrines
F Chehade, M Ghosn, N Hammoud, G Mouharram… - Médecine Nucléaire, 2015 - Elsevier
Résumé Les modalités d'imagerie des tumeurs neuroendocrines ont évolué au cours des
dernières années et de nouveaux radiopharmaceutiques à visée diagnostique et …
dernières années et de nouveaux radiopharmaceutiques à visée diagnostique et …